BioVaxys Technology Corp. Extends Closing Date for Private Placement Offering

BioVaxys Technology Corp. Announces Extension of Offering Closing Date

BioVaxys Technology Corp. has declared an important update regarding its earlier communicated brokered private placement offering. The extension of the closing date is notable as it comes at a crucial moment for the Company, indicating both strategic finance planning and ongoing commitment to its developmental goals in the biotech sector.

The offering consists of a minimum of 5,714,285 units priced at $0.35 each, with a potential maximum of 8,571,428 units, which could yield gross proceeds ranging from $2 million to $3 million. Each unit includes a post-consolidation common share along with a purchase warrant that offers the right to acquire additional shares at a later date, at a fixed price of $0.50 for up to three years following the offering's closure.

BioVaxys has partnered with Enclave Capital LLC, D12 Capital Markets Inc., and Foundation Markets Inc. as agents for this offering. These firms will assist in facilitating the financing and will earn commissions based on the funds raised, showing the commitment of external partners to support BioVaxys's ambitions.

Use of Proceeds

The funds generated from this offering are earmarked primarily for research and development, invigorating corporate operations, and strengthening working capital. This underscores BioVaxys’s aim to enhance its pipeline of innovative biopharmaceutical products and services, specifically in immunotherapy and oncology.

The closing of this offering is expected within 45 days, contingent on the satisfaction of various conditions, including approval from the Canadian Securities Exchange (CSE). Additionally, the offering will be conducted under the LIFE framework, providing an exemption from typical prospectus requirements feasible in most Canadian provinces.

To comply with the relevant regulations, the offered units will not carry resale restrictions according to Canadian securities regulations. This facet may positively influence investor sentiment, potentially widening the appeal of the offering.

Company Background and Outlook

BioVaxys is a biopharmaceutical entity based in British Columbia, focused on creating novel immunotherapies for severe health conditions, including cancer and infectious diseases. The Company’s proprietary platforms, including the DPX™ immune-educating technology, aim to provoke targeted immune responses, innovating new treatment methods that could redefine current medical practices.

The focus on advanced biological treatments positions BioVaxys as a key player in the rapidly escalating biotech landscape, particularly amidst increasing global health concerns. The anticipated benefits from the funds raised will bolster its competitive edge, elevate research capabilities, and expedite product developments, essential during this pivotal phase.

Investors are urged to review the amended offering document dated July 14, 2025, available through BioVaxys’s profile on SEDAR and the Company's official website. This document offers comprehensive details crucial for making informed investment decisions.

Final Note on Regulatory Compliance

It’s essential to highlight that this announcement does not serve as a solicitation for securities sales, particularly to American investors, owing to regulatory restrictions. Both the disclosure and the offering are strictly within the confines of Canadian laws, ensuring all compliance requirements are met thoroughly.

As BioVaxys continues its journey in the biopharmaceutical industry, stakeholders are encouraged to keep a close eye on forthcoming announcements regarding the consolidation of shares and the offering closure details.

For further inquiries or to connect with BioVaxys, visit www.biovaxys.com or reach out to the company directly through their contact channels.

This proactive approach to funding and innovation sketches a promising future for BioVaxys and its stakeholders, paving the way for scientific and financial opportunities in the health technology sector.